CN104435567A - Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout - Google Patents
Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout Download PDFInfo
- Publication number
- CN104435567A CN104435567A CN201410626212.0A CN201410626212A CN104435567A CN 104435567 A CN104435567 A CN 104435567A CN 201410626212 A CN201410626212 A CN 201410626212A CN 104435567 A CN104435567 A CN 104435567A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- gout
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 47
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 240000006509 Gynostemma pentaphyllum Species 0.000 title abstract 3
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract description 63
- 239000002994 raw material Substances 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 abstract description 24
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 241000195954 Lycopodium clavatum Species 0.000 abstract description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 2
- 244000124853 Perilla frutescens Species 0.000 abstract description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 abstract 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 abstract 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 abstract 1
- 235000004347 Perilla Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 229940010454 licorice Drugs 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 16
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 16
- 229940116269 uric acid Drugs 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 201000001431 Hyperuricemia Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 235000019640 taste Nutrition 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 235000019890 Amylum Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 241000331777 Arisaema balansae Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 241001279228 Campylotropis hirtella Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000612122 Myrsine Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/424—Gynostemma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicinal composition, particularly relates to a tradtional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout and belongs to the technical field of medicine. The traditional Chinese medicinal composition for treating gout is a medicament prepared from the following medicinal raw materials in parts by weight: 15-35 parts of perilla, 3-15 parts of root of red-rooted salvia, 2-8 parts of gynostemma pentaphyllum, 3-8 parts of rhizoma tupistrae chinensis, 3-8 parts of common clubmoss herb and 1-5 parts of licorice. The traditional Chinese medicinal composition for treating gout, prepared by combining six medicinal raw materials according to a proportion, has a synergistic function and a significant treatment effect of treating gout, and does not have obvious side effect or adverse response.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, be specifically related to a kind of Chinese medicine composition of the treatment gout containing Herb Gynostemmae Pentaphylli, belong to medical art.
Background technology
Gout is also known as hyperuricemia, and sickness rate is high, healing is difficult, recurrent exerbation, belongs to the metabolic disease that disorders of purine metabolism causes.Gout is multiple is born in middle-aged and elderly people, overweight people and brain worker, the gouty acute arthritis recurrent exerbation that its clinical characters is hyperuricemia and causes thus, tophaceous deposition, tophaceous chronic arthritis and joint deformity etc., dumb for main clinical manifestation with redness and swelling of joints, burning pain, recurrent exerbation, joint motion.Often involving kidney causes chronic interstitial nephritis and uric acid kidney stones to be formed.Increase reason according to uric acid in blood and can be divided into constitutional and the large class of Secondary cases two.The cause of disease of primary gout is caused by congenital purine metabolic disturbance, belongs to heritability.The cause of disease of secondary gout, can be caused by many reasons such as nephropathy, leukemia, medicine, foods, be apt to occur in male and menopausal woman.
The Western medicine being used for the treatment of gout at present mainly contains: colchicine, Phenylbutazone or crovaril, indometacin, ibuprofen (ibvprofen, ibuprofen), piroxicam (piroxicanum), naproxen (naproxen congex), ACTH and prednisone etc.But said medicine can only stablize the state of an illness mostly, gout can not be effected a radical cure; Serious side effect also can be caused to cause the infringement of hepatic and renal function; Even if Emergent therapy effectively can not recur by symptom management, and drug resistance and repellence can be produced, even there will be leukopenia, cardiac function is impaired, hepatic and renal function is impaired, stimulating intestine and stomach system, aplastic anemia, cause the complication such as diabetes.
In Chinese medicine, gout belongs to " arthromyodynia " category, " treatise on blood trouble ": " gout, general numbness and hypoesthesia, limbs pain, modern name gout, Gu say arthromyodynia ".Increasing expert thinks, from the organic conception of the traditional Chinese medical science, treats with Chinese medicine integral syndrome differentiation, the good footpath of another bar for the treatment of gout of can yet be regarded as; Not only the toxic and side effects of Chinese medicine itself is little, and can reduce Western medicine dose, overcomes the huge toxic and side effects taken merely Western medicine for a long time and bring.
Summary of the invention
To the object of the invention is to overcome in prior art existing Western medicine side effect large, treat halfway above-mentioned deficiency, a kind of Chinese medicine composition of the treatment gout containing Herb Gynostemmae Pentaphylli is provided, this traditional Chinese medicine composition for treating gout good effect, instant effect, and little to patient body side effect.
In order to realize foregoing invention object, the invention provides following technical scheme:
Containing a Chinese medicine composition for the treatment gout of Herb Gynostemmae Pentaphylli, it is prepared from by the medicinal raw material of following weight proportion: Folium Perillae 15 ~ 35 parts, Radix Salviae Miltiorrhizae 3 ~ 15 parts, Herb Gynostemmae Pentaphylli 2 ~ 8 parts, Rhizoma Tupistrae Chinensis 3 ~ 8 parts, Herba Lycopodii 3 ~ 8 parts, 1 ~ 5 part, Radix Glycyrrhizae.Described various medicinal raw material is the Chinese crude drug meeting country or provincial standard and specify.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Folium Perillae is 20 ~ 30 parts.Preferred, part by weight shared by Folium Perillae is 25 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Radix Salviae Miltiorrhizae is 5 ~ 10 parts.Preferred, part by weight shared by Radix Salviae Miltiorrhizae is 8 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Herb Gynostemmae Pentaphylli is 4 ~ 7 parts.Preferred, part by weight shared by Herb Gynostemmae Pentaphylli is 5 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Rhizoma Tupistrae Chinensis is 5 ~ 7 parts.Preferred, part by weight shared by Rhizoma Tupistrae Chinensis is 6 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Herba Lycopodii is 5 ~ 7 parts.Preferred, part by weight shared by Herba Lycopodii is 6 parts.
Preferably, in above-mentioned medicinal raw material proportioning, part by weight shared by Radix Glycyrrhizae is 2 ~ 4 parts.Preferred, part by weight shared by Radix Glycyrrhizae is 3 parts.
The Chinese medicine composition for the treatment of gout of the present invention, the active component of medicinal raw material can be extracted according to extracting method conventional on Chinese materia medica, add pharmaceutically acceptable carrier or/and adjuvant, as starch, dextrin, microcrystalline cellulose, amylum pregelatinisatum, magnesium stearate, micropowder silica gel, sucrose, carboxymethyl starch sodium, hydroxypropyl emthylcellulose, vegetable oil, lecithin, Polyethylene Glycol, propylene glycol, ethyl hydroxybenzoate etc., make dosage form suitable on pharmaceutics, as granule, tablet, hard capsule, oral liquid, soft capsule, drop pill, water pill etc.
The extracting method of Chinese medicine composition of the present invention can adopt but be not limited to following methods:
(1) get each medicinal raw material by formula proportion, in medicinal raw material, add 60 ~ 80% ethanol or the water of medicinal raw material volume 8 ~ 10 times; Reflux, extract, 2 ~ 3 times; Extraction time is respectively 1 ~ 2h; Collect merge extractive liquid, and extracting solution is condensed into extractum, dry, obtain the extract of medicinal raw material of the present invention.
(2) in above-mentioned extract, add pharmaceutic adjuvant and be mixed and made into acceptable various pharmaceutical dosage form on pharmaceutics.
According to the needs of the various drug form of preparation, medicine of the present invention also can add suitable pharmaceutic adjuvant as filler, disintegrating agent, binding agent, lubricant, antiseptic etc. in preparation process.
Compared with prior art, beneficial effect of the present invention:
The present invention treats the Chinese medicine composition of gout, be inventor based on the pathogenetic understanding of motherland's medical science to gout, according to oneself clinical experience for many years, first from numerous Chinese medicine, determine the effective Chinese medicine of a series for the treatment of gouts, repeatedly verify through clinical again, screen.Wherein, Folium Perillae, calls red Soviet Union, red Soviet Union, purple Soviet Union, wrinkle Folium Perillae; For the band branch tender leaf of Labiatae Perilla plant Folium Perillae; Pungent, warm; Enter spleen, lung meridian; There is effect of expelling cold and relieving exterior syndrome, regulating the flow of QI to ease the stomach; For diseases such as anemofrigid cold, headache, cough, distension and fullness of the chest and abdomen.Radix Salviae Miltiorrhizae, another name Arisaema balansae Engl., Radix Campylotropis Hirtella (Herba Myrsines Africanae), Herba Wedeliae Wallichii root, blood mountain root, RADIX SALVIAE MILTIORRHIZAE, Radix Salviae Miltiorrhizae; For the dry root and rhizome of labiate Radix Salviae Miltiorrhizae.Hardship, is slightly cold; GUIXIN, Liver Channel; There is effect of stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, the relieving restlessness that clears away heart-fire; Swell and ache for menoxenia, amenorrhea dysmenorrhea, lump in the abdomen, breast ventral spine pain, pyretic arthralgia pain, skin infection, dysphoria and insomnia, hepatosplenomegaly, the disease such as angina pectoris.Herb Gynostemmae Pentaphylli, another name Herba Gynostemmatis, Herba Gynostemmatis, Herb Gynostemmae Pentaphylli.Hardship, cold; Return lung, spleen, kidney channel; There is effect of heat-clearing and toxic substances removing, eliminating phlegm and stopping cough; For chronic bronchitis, infectious hepatitis, nephritis, gastroenteritis.Rhizoma Tupistrae Chinensis is the rhizome of liliaceous plant Rhizoma Tupistrae Chinensis; Sweet and slightly bitter taste, cold in nature, there is effect of nourishing yin and purging fire, promoting blood flow to regulate menstruation; For controlling the diseases such as consumptive fever cough, rheumatic arthralgia, menoxenia, traumatic injury.Herba Lycopodii, calls Lycopodium clavatum, lion tail, lion grass, green hair stretches muscle etc., is the dry herb of lycopsid Lycopodium clavatum; Mildly bitter flavor, pungent, warm in nature; Return liver,spleen,kidney warp.There is effect of expelling wind and removing dampness, relaxing muscles and tendons and activating QI and blood in the collateral; For joint aches, the diseases such as joint stuffiness.Radix Glycyrrhizae is the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L.; Sweet in the mouth, property is put down; GUIXIN, lung, spleen, stomach warp; There is effect of invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription; For weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, gastral cavity abdomen, the anxious disease such as pain, carbuncle sore tumefacting virus of extremity contraction.Above-mentioned 6 taste Chinese herbal medicine, flavour of a drug are few but function is complete, 6 taste medicinal raw materials are by after described proportioning combination, treatment gout has Synergistic function, and through clinical research test, Chinese medicine composition of the present invention is used for the treatment of gout short treating period, instant effect, administration is after 4 days, can take effect, and evident in efficacy, there is not obvious adverse reaction during patient consumes.
Detailed description of the invention
Below in conjunction with test example and detailed description of the invention, the present invention is described in further detail, but this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment, and all technology realized based on content of the present invention all belong to scope of the present invention.
In embodiments of the invention and comparative example, ethanol used is the aqueous solution of ethanol, and the percentage composition of ethanol, if no special instructions, is volumn concentration.
Embodiment 1
The Chinese medicine composition of the treatment gout of the present embodiment is be prepared from by the medicinal raw material of following weight proportion: Folium Perillae 25g, Radix Salviae Miltiorrhizae 8g, Herb Gynostemmae Pentaphylli 5g, Rhizoma Tupistrae Chinensis 6g, Herba Lycopodii 6g, Radix Glycyrrhizae 3g.
The extracting method of above-mentioned medicinal raw material:
(1) get each medicinal raw material by formula proportion, in medicinal raw material, add 60 ~ 80% ethanol or the water of medicinal raw material volume 8 ~ 10 times; Reflux, extract, 2 ~ 3 times; Extraction time is respectively 1 ~ 2h; Collect merge extractive liquid, and extracting solution is concentrated into relative density 1.20 (80 DEG C), obtain the extract of embodiment 1 medicinal raw material.
(2) in above-mentioned extract, add the soluble starch of extract weight 2 times of weight, granulate, dry, be distributed into bag, obtain granule.
Embodiment 2
The Chinese medicine composition of the treatment gout of the present embodiment is be prepared from by the medicinal raw material of following weight proportion: Folium Perillae 35g, Radix Salviae Miltiorrhizae 13g, Herb Gynostemmae Pentaphylli 2g, Rhizoma Tupistrae Chinensis 7g, Herba Lycopodii 3g, Radix Glycyrrhizae 1g.
Extract the active component of medicinal raw material by medicinal raw material extracting method in embodiment 1, obtain the Chinese medicine composition that embodiment 2 treats gout.
Embodiment 3
The Chinese medicine composition of the treatment gout of the present embodiment is be prepared from by the medicinal raw material of following weight proportion: Folium Perillae 20g, Radix Salviae Miltiorrhizae 8g, Herb Gynostemmae Pentaphylli 6g, Rhizoma Tupistrae Chinensis 7g, Herba Lycopodii 6g, Radix Glycyrrhizae 3g.
Extract the active component of medicinal raw material by medicinal raw material extracting method in embodiment 1, obtain the Chinese medicine composition that embodiment 3 treats gout.
Comparative example
The Chinese medicine composition of the treatment gout of this comparative example is be prepared from by the medicinal raw material of following weight proportion: Folium Perillae 25g, Radix Salviae Miltiorrhizae 8g, Rhizoma Tupistrae Chinensis 6g, Herba Lycopodii 6g, Radix Glycyrrhizae 3g.
Extract the active component of medicinal raw material by medicinal raw material extracting method in embodiment 1, obtain the Chinese medicine composition of comparative example treatment gout.
Pharmacodynamics and toxicity test:
In order to the efficacy and saferry of proved invention medicine, inventors performed pharmacodynamics and toxicity test investigation.The research method adopted and result of the test as follows:
1, test material
(1) medicine and reagent:
According to the Chinese medicine composition of embodiment 1 prepared by embodiment 1;
According to the Chinese medicine composition of comparative example prepared by comparative example;
Colchicine: be Yunnan Plant Pharmaceutical Industry Co., Ltd.'s product.
(2) animal: Kunming mouse, is provided by Sichuan institute of antibiotics Experimental Animal Center.
2, test method and result
(1) on the impact of hyperuricemia Mouse Blood uric acid level
Get Kunming mouse 50, male and female are use all, and body weight 18 ~ 22g is divided into five groups at random, often organize 10, first group is normal saline group, and second group is drug study group of the present invention (8g raw medicinal herbs/kg), 3rd group is positive controls, and the 4th group is matched group 1, and the 5th group is model group.
Normal saline is gavaged by the dosage of 8g/kg to first group, second group gavages the Chinese medicine composition of the embodiment of the present invention 1 preparation by the dosage of 8g raw medicinal herbs/kg, 3rd group gavages colchicine by the drug dose of 0.1mg/kg, 4th group gavages Chinese medicine composition prepared by comparative example by the dosage of 8g raw medicinal herbs/kg, do not do any process for 5th group, every day 1 time, continuous 4d.
After last administration 1h, except normal saline group, all the other each group, namely second group to the 5th group, animal Intraperitoneal injection of hypoxanthine 1mg/kg, causes mice hyperuricemia, and normal saline group presses 1mg/kg injecting normal saline.0.5h after injection, plucks eyeball to each treated animal and gets blood, and the blood obtained after centrifugal 15min, is got serum and surveyed Level of Serum Uric Acid under the speed conditions of 3000r/min.Table 1 be each experimental group and matched group after treatment, the statistical result of blood uric acid measured value.
Table 1
Note: compare with model group:
*p<0.01; Compare with matched group 1:
▲ ▲p<0.01.
In table 1, it is 169 ± 32umol/l that drug study group of the present invention records Level of Serum Uric Acid: close with the Level of Serum Uric Acid 128 ± 27umol/l of normal saline group and the Level of Serum Uric Acid 152 ± 28umol/l of positive controls; Level of Serum Uric Acid 748 ± 103umol/l that relative model group records reduces about 580umol/l, and the statistical result of drug study group of the present invention is relative to model group P<0.01, has significant difference; The traditional Chinese medicine composition for treating gout that the present invention treats gout has good curative effect.
And in table 1, it is 248 ± 23umol/l that matched group 1 records Level of Serum Uric Acid, relative drug study group of the present invention records Level of Serum Uric Acid 169 ± 32umol/l and exceeds about 80umol/l.And the blood uric acid measured value of drug study group of the present invention is compared with the blood uric acid measured value P < 0.01 of matched group 1, has significant difference.Learn thus, 6 taste medicinal raw materials are by after described weight proportion combination, and have Synergistic function, can significantly improve the curative effect of Chinese medicine composition, lack any component, the curative effect of Chinese medicine composition all significantly declines.
In sum, the present invention treats the Chinese medicine composition of gout, and the short treating period for the treatment of gout, instant effect, administration can take effect for 4 days, evident in efficacy.Administration injected hypoxanthine after 4 days, and the blood uric acid measured value of drug study group of the present invention all can not occur significantly to raise phenomenon; 6 taste medicinal raw materials, by after described weight proportion combination, have Synergistic function, can significantly improve the curative effect of Chinese medicine composition.Lack any component, its curative effect all significantly declines, and as matched group 1, after injection hypoxanthine, the blood uric acid measured value recording the relative drug study group of the present invention of Level of Serum Uric Acid raises about 80umol/l.
Claims (10)
1., containing a Chinese medicine composition for the treatment gout of Herb Gynostemmae Pentaphylli, it is characterized in that: it is prepared from by the medicinal raw material of following weight proportion: Folium Perillae 15 ~ 35 parts, Radix Salviae Miltiorrhizae 3 ~ 15 parts, Herb Gynostemmae Pentaphylli 2 ~ 8 parts, Rhizoma Tupistrae Chinensis 3 ~ 8 parts, Herba Lycopodii 3 ~ 8 parts, 1 ~ 5 part, Radix Glycyrrhizae.
2. the Chinese medicine composition for the treatment of gout according to claim 1, is characterized in that: part by weight shared by Folium Perillae is 20 ~ 30 parts.
3. the Chinese medicine composition for the treatment of gout according to claim 2, is characterized in that: part by weight shared by Folium Perillae is 25 parts.
4. the Chinese medicine composition for the treatment of gout according to claim 1, is characterized in that: part by weight shared by Radix Salviae Miltiorrhizae is 5 ~ 10 parts.
5. the Chinese medicine composition for the treatment of gout according to claim 4, is characterized in that: part by weight shared by Radix Salviae Miltiorrhizae is 8 parts.
6. the Chinese medicine composition for the treatment of gout according to claim 1, is characterized in that: part by weight shared by Herb Gynostemmae Pentaphylli is 4 ~ 7 parts.
7. the Chinese medicine composition for the treatment of gout according to claim 6, is characterized in that: part by weight shared by Herb Gynostemmae Pentaphylli is 5 parts.
8. the Chinese medicine composition for the treatment of gout according to claim 1, is characterized in that: part by weight shared by Rhizoma Tupistrae Chinensis is 5 ~ 7 parts.
9. the Chinese medicine composition for the treatment of gout according to claim 1, is characterized in that: part by weight shared by Herba Lycopodii is 5 ~ 7 parts.
10. the Chinese medicine composition for the treatment of gout according to claim 1, is characterized in that: part by weight shared by Radix Glycyrrhizae is 2 ~ 4 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626212.0A CN104435567A (en) | 2014-11-07 | 2014-11-07 | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410626212.0A CN104435567A (en) | 2014-11-07 | 2014-11-07 | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104435567A true CN104435567A (en) | 2015-03-25 |
Family
ID=52882828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410626212.0A Pending CN104435567A (en) | 2014-11-07 | 2014-11-07 | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435567A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105998762A (en) * | 2016-05-09 | 2016-10-12 | 张钊 | Fiveleaf gynostemma herb containing healthcare pharmaceutical composition for preventing hyperlipidemia, hypertension and hyperglycemia and gout |
| CN107875266A (en) * | 2017-11-28 | 2018-04-06 | 高大朋 | For treating the oral traditional Chinese medicine of gout and tophus |
| CN114931618A (en) * | 2022-02-23 | 2022-08-23 | 广州大医中医医院有限公司 | Traditional Chinese medicine composition for treating gout |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085169A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Traditional Chinese medicine for treating uric acid nephritis |
| CN102940709A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating gout |
| CN102940747A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating gout |
| CN102940750A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating gout |
| CN102940695A (en) * | 2012-11-01 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating gout |
| CN104095940A (en) * | 2014-08-06 | 2014-10-15 | 成都医路康医学技术服务有限公司 | Traditional Chinese medicine composition for treating gout |
-
2014
- 2014-11-07 CN CN201410626212.0A patent/CN104435567A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085169A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Traditional Chinese medicine for treating uric acid nephritis |
| CN102940709A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating gout |
| CN102940747A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating gout |
| CN102940750A (en) * | 2012-10-31 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating gout |
| CN102940695A (en) * | 2012-11-01 | 2013-02-27 | 成都医路康医学技术服务有限公司 | Medicine composition for treating gout |
| CN104095940A (en) * | 2014-08-06 | 2014-10-15 | 成都医路康医学技术服务有限公司 | Traditional Chinese medicine composition for treating gout |
Non-Patent Citations (4)
| Title |
|---|
| 胡殿宇等主编: "《临床医学概论》", 31 January 2013 * |
| 赵铮蓉等: ""绞股蓝提取物的抗痛风活性部位筛选"", 《中华中医药学刊》 * |
| 陈东银等主编: "《痛风合理用药与食疗》", 31 August 2014 * |
| 黎莉 等: ""中草药来源的黄嘌呤氧化酶抑制剂的研究进展"", 《中药材》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105998762A (en) * | 2016-05-09 | 2016-10-12 | 张钊 | Fiveleaf gynostemma herb containing healthcare pharmaceutical composition for preventing hyperlipidemia, hypertension and hyperglycemia and gout |
| CN107875266A (en) * | 2017-11-28 | 2018-04-06 | 高大朋 | For treating the oral traditional Chinese medicine of gout and tophus |
| CN114931618A (en) * | 2022-02-23 | 2022-08-23 | 广州大医中医医院有限公司 | Traditional Chinese medicine composition for treating gout |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104338062A (en) | Chinese medicinal preparation for treating stomachache and diarrhea | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN104491236A (en) | Traditional Chinese medicine preparation for treating essential hypertension and preparation method for traditional Chinese medicine preparation | |
| CN103446445B (en) | Traditional Chinese medicine preparation for treating qi-yin deficiency-type chronic bronchitis and preparation method thereof | |
| CN104337989A (en) | Traditional Chinese medicine composition containing centipeda minima and frankincense for treating gout | |
| CN105267559A (en) | Diabetic peripheral neuropathy treatment medicine and manufacturing method thereof | |
| CN104383486A (en) | Medicament for treating bronchitis of children | |
| CN104225507A (en) | Chinese medicine for treating limb paralysis and pain caused by cerebral hemorrhage | |
| CN104337909B (en) | A kind of Chinese medicine composition of the treatment gout containing Aspongopus | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN104435079A (en) | Traditional Chinese medicinal composition for treating gout | |
| CN105106674A (en) | Traditional Chinese medicine composition for treating senile skin pruritus and preparation method of composition | |
| CN104547859A (en) | Application of traditional Chinese medicine preparation in preparation of medicine for treating chronic tracheitis | |
| CN108853340A (en) | A kind of Chinese medicine of nourishing the liver and kidney and preparation method thereof | |
| CN103845690A (en) | Medicament for treating geriatric depression | |
| CN104337889B (en) | A kind of Chinese medicine composition of the treatment gout containing Lumbricus | |
| CN104398564A (en) | Tripterygium wilfordii containing Chinese medicinal composition for treatment of gout | |
| CN104435141A (en) | Traditional Chinese medicine composition containing winged euonymus twig and used for treating diabetes | |
| CN104436017A (en) | Traditional Chinese medicine composition containing caulis akebiae for treating gout | |
| CN104547945A (en) | Traditional Chinese medicine preparation for treating scrofula and preparation method of traditional Chinese medicine preparation | |
| CN104666468A (en) | Pharmaceutical composition for treating hyperthyroidism and scrofula | |
| CN104288541A (en) | Chinese herbal preparation for treating stroke and sequelae of stroke, as well as preparation method thereof | |
| CN104436021A (en) | Arctium-containing traditional Chinese medicine composition for treating diabetes mellitus | |
| CN103356984B (en) | Traditional Chinese medicine composition for preventing and treating female iron deficiency anemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150325 |